This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 26 November - 2 December 2023 and includes updates on human infection with influenza A(H1N2)v, influenza A(H5N1), an overview of respiratory virus epidemiology in the EU/EEA, respiratory infections due to Mycoplasma pneumoniae in the EU/EEA, HIV/AIDS surveillance 2023 (2022 data), West Nile virus, SARS-CoV-2 variant classification, and poliomyelitis.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19 - 25 November 2023 and includes updates on updates SARS-CoV-2 variant classifications, the increase of pediatric respiratory infections in China, Avian influenza in fur farms, West Nile virus, cholera, and an overview of respiratory virus epidemiology.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 12 - 18 November 2023 and includes updates on SARS-CoV-2 variant classification, West Nile virus, multistate outbreak of salmonella, and an overview of respiratory virus epidemiology in the EU/EEA.
Joint statement by the European Centre for Disease Prevention and Control, European Chemicals Agency, European Environment Agency, European Food Safety Authority and European Medicines Agency.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 5 - 11 November 2023 and includes updates on SARS-CoV-2 variants, an overview of respiratory virus epidemiology in the EU/EEA, West Nile Virus, measles, diphtheria, Middle East respiratory virus syndrome, chikungunya, and dengue.
This report presents the results of the ninth round of the external quality assessment (EQA-9) scheme for Listeria monocytogenes (L. monocytogenes) typing, organised for national public health reference laboratories (NPHRLs) providing data to the Food- and Waterborne Diseases and Zoonoses Network (FWD-Net), managed by ECDC.
From 1 January–24 October 2023, 335 laboratory-confirmed Salmonella Enteritidis ST11 cases belonging to three distinct microbiological clusters have been reported in 14 EU/EEA countries, the United Kingdom and the United States, affecting all age groups.